[A16-62] Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 02.01.2017
Commission awarded on 29.09.2016 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A17-32||Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-05||Ceritinib (lung cancer) - Addendum to Commission A16-62||Commission completed|
|A15-24||Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|